查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576806

基因转移技术市场：按类型、应用、最终用户、适应症分类 - 全球预测 2025-2030

Gene Delivery Technologies Market by Type (Non-Viral Vector, Viral Vector), Application (Cell Therapy, Gene Therapy, Research), End User, Disease Indication - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年基因转移技术市场价值为43.4亿美元，预计到2024年将达到49.4亿美元，复合年增长率为14.82%，到2030年将达到114.3亿美元。

基因转移技术涉及将遗传物质引入细胞以修改基因表现、修復缺陷基因和增强免疫反应的方法和机制。这项技术对于基因治疗的进步至关重要，基因治疗旨在透过针对基因的根源来治疗或预防疾病。基因转殖的主要应用包括治疗遗传疾病、癌症和感染疾病，并在疫苗开发中发挥越来越大的作用。最终用途包括製药和生物技术公司、研究和学术机构以及专注于先进基因治疗的医疗机构。

主要市场统计
基准年[2023] 43.4亿美元
预测年份 [2024] 49.4亿美元
预测年份 [2030] 114.3亿美元
复合年增长率（%） 14.82%

市场成长受到遗传疾病日益普及、基因组学进步以及对标靶治疗需求迅速增加的影响。一个主要的商机在于开发非病毒传递系统，该系统可以减轻病毒载体引起的免疫反应并提高患者的安全。抓住这些机会的研究包括投资新的给药系统和个人化医疗方法的研究、与研究机构建立策略伙伴关係以及扩大临床试验网络。该市场还面临高昂的开发成本、严格的法律规范以及基因改造的伦理问题等限制。此外，在不引起副作用的情况下有效递送至目标细胞的技术挑战也构成了主要障碍。

研究和创新将致力于提高递送系统的功效和安全性、开发靶向奈米颗粒载体以及利用 CRISPR 技术进行精确基因组编辑。找到这些挑战的解决方案可以带来显着的业务成长，特别是在个人化医疗和免疫疗法领域。基因转移技术市场的本质是高度动态的，其基础是不断的技术进步和不断变化的监管环境。利用基因组编辑和递送方法的尖端研究的公司可能会透过提供满足未满足的医疗需求的创新解决方案而处于领先地位，从而确保在这个快速发展的领域的竞争优势。

市场动态：揭示快速发展的基因转移技术市场的关键市场洞察

基因转移技术市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 扩大农业和兽医领域的应用
    • 学术机构与生物製药公司合作开发创新解决方案
    • 政府对基因治疗进展的承诺和监管支持
    • 用于有效基因转移的新型病毒和非病毒载体的出现
  • 市场限制因素
    • 实现治疗基因高效、标靶化递送的技术挑战
    • 基因转移技术的专家和专业知识数量有限
  • 市场机会
    • 创新基因转殖方法治疗罕见遗传疾病取得重大进展
    • 开发非病毒载体以实现抑制免疫反应的更安全基因治疗的巨大潜力
    • 扩大基因治疗在黄斑部病变和关节炎等老龄化疾病的应用
  • 市场挑战
    • 高开发成本及研发投资影响基因转殖技术市场
    • 基因转移领域的智慧财产权和专利挑战影响市场动态

波特五力：驾驭基因转殖技术市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解基因转移技术市场的外部影响

外部宏观环境因素在塑造基因转移技术市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解基因转殖技术市场的竞争状况

对基因转移技术市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵基因转殖技术市场供应商绩效评估

FPNV定位矩阵是评估基因转殖技术市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了基因转移技术市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对基因转移技术市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大应用到农业和兽医领域
      • 合作学术机构和生物製药公司提供创新解决方案
      • 政府对基因治疗进展的承诺和监管支持
      • 用于有效基因传递的新型病毒和非病毒载体的出现
    • 抑制因素
      • 实现治疗基因高效、标靶递送的技术挑战
      • 基因转移技术的熟练专业人员和专业知识有限
    • 机会
      • 创新基因递送方法为罕见遗传疾病治疗取得重大突破
      • 开发非病毒载体以实现更安全的限制免疫反应的基因治疗具有巨大潜力
      • 扩大基因治疗在老龄化疾病（如老龄化黄斑部病变和关节炎）的应用
    • 任务
      • 基因转殖技术市场受高开发成本及研发投入影响
      • 基因传递领域的智慧财产权和专利挑战影响市场动态
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 基因转殖技术市场：依类型

  • 非病毒载体
    • 化学法
      • 脂质体
      • 聚合物基
    • 物理方法
      • 电穿孔
      • 显微注射
      • 粒子撞击
  • 病毒载体
    • 腺结合病毒
    • 腺病毒
    • 慢病毒
    • 逆转录病毒

第七章 基因转殖技术市场：依应用分类

  • 细胞疗法
  • 基因治疗
    • 单基因疾病
    • 多基因疾病
  • 调查
  • 疫苗
    • 细菌疫苗
    • 病毒疫苗

第八章 基因转殖技术市场：依最终使用者分类

  • 生技公司
  • 合约调查机构
  • 製药公司
  • 调查机构

第九章基因转殖技术市场：依疾病适应症

  • 癌症
  • 心血管疾病
  • 遗传疾病
    • 囊肿纤维化
    • 肌肉萎缩症
  • 感染疾病

第十章 北美和南美基因转殖技术市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区基因转殖技术市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲基因转殖技术市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C021C

The Gene Delivery Technologies Market was valued at USD 4.34 billion in 2023, expected to reach USD 4.94 billion in 2024, and is projected to grow at a CAGR of 14.82%, to USD 11.43 billion by 2030.

Gene delivery technologies involve the methods and mechanisms through which genetic material is introduced into cells to modify gene expression, repair defective genes, or bolster the immune response. This technology is essential in the advancement of gene therapy, which aims to treat or prevent diseases by targeting their genetic roots. The main applications of gene delivery include the treatment of genetic disorders, cancer, and infectious diseases, with an expanding role in vaccine development. The end-use scope comprises pharmaceutical and biotechnology companies, research and academic institutions, and healthcare facilities focused on advanced genetic treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 4.34 billion
Estimated Year [2024] USD 4.94 billion
Forecast Year [2030] USD 11.43 billion
CAGR (%) 14.82%

Market growth is influenced by the increasing prevalence of genetic disorders, advancements in genomics, and a surge in demand for targeted therapies. A significant opportunity lies in the development of non-viral delivery systems, which mitigate immune responses induced by viral vectors and enhance patient safety. Recommendations for capturing these opportunities include investing in research for novel delivery systems and personalized medicine approaches, forming strategic partnerships with research institutions, and expanding clinical trial networks. The market also faces limitations, such as high development costs, stringent regulatory frameworks, and ethical concerns regarding genetic modifications. Moreover, the technical challenges in effective delivery to target cells without inducing adverse reactions pose significant hurdles.

Research and innovation can be directed towards improving the efficacy and safety of delivery systems, developing targeted nanoparticle carriers, and utilizing CRISPR technology for precise genome editing. Uncovering solutions for these challenges could result in substantial business growth, particularly in personalized medicine and immunotherapy sectors. The nature of the gene delivery technology market is highly dynamic, underscored by constant technological progress and evolving regulatory landscapes. Businesses that leverage cutting-edge research in genome editing and delivery methodologies are likely to lead in providing transformative solutions that meet unmet medical needs, thus ensuring a competitive edge in this rapidly advancing field.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Gene Delivery Technologies Market

The Gene Delivery Technologies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of applications in agriculture and veterinary sciences
    • Collaboration between academic institutions and biopharmaceutical companies for innovative solutions
    • Government initiatives and regulatory support for gene therapy advancements
    • Emergence of novel viral and non-viral vectors for efficient gene delivery
  • Market Restraints
    • Technical challenges in achieving efficient and targeted delivery of therapeutic genes
    • Limited availability of skilled professionals and expertise in gene delivery technologies
  • Market Opportunities
    • Innovative gene delivery methods for rare genetic disorder treatments showing significant advancements
    • High potential in developing non-viral vectors for safer gene therapies limiting immune responses
    • Expanding gene therapy applications for age-related conditions such as macular degeneration and arthritis
  • Market Challenges
    • High development costs and R&D investments impacting gene delivery technologies market
    • Intellectual property and patent challenges in the gene delivery space affecting market dynamics

Porter's Five Forces: A Strategic Tool for Navigating the Gene Delivery Technologies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Gene Delivery Technologies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Gene Delivery Technologies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Gene Delivery Technologies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Gene Delivery Technologies Market

A detailed market share analysis in the Gene Delivery Technologies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Gene Delivery Technologies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Gene Delivery Technologies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Gene Delivery Technologies Market

A strategic analysis of the Gene Delivery Technologies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Gene Delivery Technologies Market, highlighting leading vendors and their innovative profiles. These include Amgen, Avalanche Biotechnologies, Beam Therapeutics, BioNTech, Bluebird Bio, CRISPR Therapeutics, Editas Medicine, GlaxoSmithKline, Intellia Therapeutics, Moderna Therapeutics, Novartis, Pfizer, REGENXBIO, Roche, Sangamo Therapeutics, Sanofi, Spark Therapeutics, uniQure, Voyager Therapeutics, and Ziopharm Oncology.

Market Segmentation & Coverage

This research report categorizes the Gene Delivery Technologies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Non-Viral Vector and Viral Vector. The Non-Viral Vector is further studied across Chemical Methods and Physical Methods. The Chemical Methods is further studied across Liposomes and Polymer Based. The Physical Methods is further studied across Electroporation, Microinjection, and Particle Bombardment. The Viral Vector is further studied across Adeno-Associated Virus, Adenovirus, Lentivirus, and Retrovirus.
  • Based on Application, market is studied across Cell Therapy, Gene Therapy, Research, and Vaccines. The Gene Therapy is further studied across Monogenic Disorders and Multigenic Disorders. The Vaccines is further studied across Bacterial Vaccines and Viral Vaccines.
  • Based on End User, market is studied across Biotechnological Companies, Contract Research Organizations, Pharmaceutical Companies, and Research Institutes.
  • Based on Disease Indication, market is studied across Cancer, Cardiovascular Diseases, Genetic Disorders, and Infectious Diseases. The Genetic Disorders is further studied across Cystic Fibrosis and Muscular Dystrophy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of applications in agriculture and veterinary sciences
      • 5.1.1.2. Collaboration between academic institutions and biopharmaceutical companies for innovative solutions
      • 5.1.1.3. Government initiatives and regulatory support for gene therapy advancements
      • 5.1.1.4. Emergence of novel viral and non-viral vectors for efficient gene delivery
    • 5.1.2. Restraints
      • 5.1.2.1. Technical challenges in achieving efficient and targeted delivery of therapeutic genes
      • 5.1.2.2. Limited availability of skilled professionals and expertise in gene delivery technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative gene delivery methods for rare genetic disorder treatments showing significant advancements
      • 5.1.3.2. High potential in developing non-viral vectors for safer gene therapies limiting immune responses
      • 5.1.3.3. Expanding gene therapy applications for age-related conditions such as macular degeneration and arthritis
    • 5.1.4. Challenges
      • 5.1.4.1. High development costs and R&D investments impacting gene delivery technologies market
      • 5.1.4.2. Intellectual property and patent challenges in the gene delivery space affecting market dynamics
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Gene Delivery Technologies Market, by Type

  • 6.1. Introduction
  • 6.2. Non-Viral Vector
    • 6.2.1. Chemical Methods
      • 6.2.1.1. Liposomes
      • 6.2.1.2. Polymer Based
    • 6.2.2. Physical Methods
      • 6.2.2.1. Electroporation
      • 6.2.2.2. Microinjection
      • 6.2.2.3. Particle Bombardment
  • 6.3. Viral Vector
    • 6.3.1. Adeno-Associated Virus
    • 6.3.2. Adenovirus
    • 6.3.3. Lentivirus
    • 6.3.4. Retrovirus

7. Gene Delivery Technologies Market, by Application

  • 7.1. Introduction
  • 7.2. Cell Therapy
  • 7.3. Gene Therapy
    • 7.3.1. Monogenic Disorders
    • 7.3.2. Multigenic Disorders
  • 7.4. Research
  • 7.5. Vaccines
    • 7.5.1. Bacterial Vaccines
    • 7.5.2. Viral Vaccines

8. Gene Delivery Technologies Market, by End User

  • 8.1. Introduction
  • 8.2. Biotechnological Companies
  • 8.3. Contract Research Organizations
  • 8.4. Pharmaceutical Companies
  • 8.5. Research Institutes

9. Gene Delivery Technologies Market, by Disease Indication

  • 9.1. Introduction
  • 9.2. Cancer
  • 9.3. Cardiovascular Diseases
  • 9.4. Genetic Disorders
    • 9.4.1. Cystic Fibrosis
    • 9.4.2. Muscular Dystrophy
  • 9.5. Infectious Diseases

10. Americas Gene Delivery Technologies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Gene Delivery Technologies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Gene Delivery Technologies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen
  • 2. Avalanche Biotechnologies
  • 3. Beam Therapeutics
  • 4. BioNTech
  • 5. Bluebird Bio
  • 6. CRISPR Therapeutics
  • 7. Editas Medicine
  • 8. GlaxoSmithKline
  • 9. Intellia Therapeutics
  • 10. Moderna Therapeutics
  • 11. Novartis
  • 12. Pfizer
  • 13. REGENXBIO
  • 14. Roche
  • 15. Sangamo Therapeutics
  • 16. Sanofi
  • 17. Spark Therapeutics
  • 18. uniQure
  • 19. Voyager Therapeutics
  • 20. Ziopharm Oncology

LIST OF FIGURES

  • FIGURE 1. GENE DELIVERY TECHNOLOGIES MARKET RESEARCH PROCESS
  • FIGURE 2. GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENE DELIVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENE DELIVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENE DELIVERY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENE DELIVERY TECHNOLOGIES MARKET DYNAMICS
  • TABLE 7. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY POLYMER BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MICROINJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PARTICLE BOMBARDMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY ADENOVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY LENTIVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RETROVIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MONOGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MULTIGENIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY BACTERIAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CYSTIC FIBROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY MUSCULAR DYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 175. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 186. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 206. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 208. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 228. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 230. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 239. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 241. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 250. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 252. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 273. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 275. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 284. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 285. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 286. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 295. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 297. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 306. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 308. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENE THERAPY, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY GENETIC DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 317. GERMANY GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 318. GERMANY GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2030 (USD MILLION)
  • TABLE 319. GERMANY GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY CHEMICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY GENE DELIVERY TECHNOLOGIES MARKET SIZE, BY PHYSICAL METHODS, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY GEN